US 8,969,302 B2
Low frequency glatiramer acetate therapyGeneral
US 8,969,302 B2
Low frequency glatiramer acetate therapy
Tech Center:
1600 Biotechnology and Organic Chemistry
Examiner:
John Ulm
Art Unit:
1649 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology
Agent:
Inventors:
Ety Klinger
Priority:
08/20/09
Filed:
02/19/13
Granted:
03/03/15
Expiration:
04/10/23
Abstract
A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.
Cooperative Patent Classification (CPC)
A61A61P3/10A61K9/0019A61P